Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin in First-Line Triple-Negative Metastatic Breast Cancer
NCT00601159Phase 2Completed
- Sponsor
- Fudan University
- Start
- Sep 2007
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, cisplatin in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Sep 2007; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00601159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00601159.